The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

A deal that would have seen Idorsia sell global rights to hypertension drug Tryvio (aprocitentan) has fallen through, leaving the cash-strapped pharma company to seek other avenues to secure funding.

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

The Tryvio REMS program was established due to the risk of birth defects associated with the ERA drug class. Prior to dispensing Tryvio, patients of reproductive potential were required to report a ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

The US pharma giant is paying $350 million upfront to Idorsia for rights to AMI therapy selatogrel and SLE candidate cenerimod in the deal, which also includes undisclosed development, regulatory ...

Under the updated terms, Idorsia will consent to Nxera Pharma assigning to Viatris its development and commercialization rights for cenerimod in Japan, South Korea and certain countries in the ...

Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...